© All rights reserved to Barnea Jaffa Lande Law offices

Ran Karmi
Adv. Ran Carmi

Electra City Tower
58 Harakevet St.
Tel Aviv
6777016

Practice areas:

Ran Karmi

Dr. Ran Karmi is a member of the firm’s Antitrust and Competition Department.

Ran advises both Israeli and foreign corporations on mergers and acquisitions, dominant and monopolistic status, restrictive arrangements, and tender agreements.

 

Ran represents the firm’s clients before the Israel Competition Authority, the Competition Tribunal, and all levels of Israeli courts in proceedings involving antitrust and competition matters, as well as in other commercial litigation.

 

He boasts extensive previous experience as an attorney specializing in intellectual property and its regulation.

 

Ran served as an antitrust research assistant to Professor Michal S. Gal and an intellectual property research assistant to Professor Niva Elkin-Koren, both at the University of Haifa. During the course of his studies at the University of Haifa, Ran served as chief counsel of the Student Union and took part in numerous and diverse academic projects.

 

Ran was awarded a Ph.D. in Law from Bar-Ilan University in 2025, with a dissertation on enhanced damages in contract law.

 

Prominent legal directory The Legal 500 ranks Ran as a Recommended Lawyer in Competition and Antitrust.

 

Prior to joining Barnea, Ran served in the antitrust and competition department of a boutique law firm.

Education:


University of Haifa, LL.M., Law and Technology Program (2nd in his class), 2011

University of Haifa, LL.B. (magna cum laude and Dean's List), 2011

University of Haifa, B.A. in Economics, 2011

Bar-Ilan University, Ph.D. in Law (Dissertation on Enhanced Damages in Contract Law), 2025

Admission:


Israel Bar Association, 2012

Insights & News - Ran Karmi:


September 10, 2025

Increased Enforcement in Pharmaceutical Sector: BMS and Neopharm to Pay ILS Tens of Millions for Delaying Entry of Competing Drug

The Israel Competition Authority (ICA) published a draft consent decree with Bristol-Myers Squibb and Neopharm, requiring payments of over ILS 44 million by the companies and ILS 200,000 by a Neopharm executive, following indications of monopolistic abuse.
September 7, 2025

US Court Rules: Most of Trump’s Tariffs Unlawful

The US Federal Court of Appeals ruled recently that most of the tariffs imposed by US President Donald Trump as part of the trade wars are unlawful. However, the court decided that, for the time being, these tariffs will remain in effect. This is a landmark decision with potentially wide-ranging implications for the US and global economies, as well as for the balance of powers within the US federal government.
September 4, 2025

Aluminum Imports to Israel Halved Following Provisional Anti-Dumping Measures

In May, the Ministry of Economy imposed a temporary guarantee on aluminum imports from China. As a result, Israeli aluminum importers have already reduced their orders from China by 50%. Simultaneously, access to the Turkish market has been almost entirely blocked for Israeli buyers.

See all news updates from Ran Karmi >

Practice areas: